NASDAQ$CNTA
Centessa Pharmaceuticals plc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results and business highlights for the second quarter of 2022.
Centessa Pharmaceuticals reported its Q2 2022 financial results, highlighting the advancement of its rare diseases and immuno-oncology pipeline. The company is on track to initiate registrational studies for SerpinPC for Hemophilia B in the second half of the year and plans to initiate clinical trials with LB101 for solid tumors after an IND filing later this year. However, they discontinued development of ZF874 following an adverse event.
- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022.
- Oncology pipeline advancing with novel LockBody® technology.
- Discontinued ZF874 for AATD.
- Multiple clinical PoC readouts expected across pipeline over next two years.
Headline financials
Revenue & EPS history
Centessa · Revenue · Quarterly
$0
Forward guidance
Centessa Pharmaceuticals expects to reach several milestones, including initiating registrational studies for SerpinPC in Hemophilia B, presenting two-year follow-up data from a Phase 2a open-label extension study for SerpinPC, and submitting an IND for LB101.
Tailwinds
- Initiate registrational studies in Hemophilia B in 2H 2022.
- Report two-year follow-up data from Phase2a open label extension study for SerpinPC in Q4 2022.
- Submit IND for LB101 in Q4 2022.
- Advance earlier stage programs and provide updates as they enter clinical studies.
- Cash runway into 2026.
Headwinds
- Discontinuation of ZF874 development.
- Adverse event involving elevated liver enzymes (AST/ALT) in a subject dosed with ZF874.
- Unlikely to achieve the desired target product profile with ZF874.
- Analyzing data from the Phase 1 study to help inform potential future development plans for back-up compounds.
- Potential future development plans for back-up compounds are uncertain.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+1.0%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+4.0%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+19.4%
Q2 2024
Best reaction
-14.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | -0.3% | +0.3% | |
| Q4 2025 | -4.2% | +6.1% | +45.9% | |
| Q3 2025 | -5.2% | -5.9% | +26.0% | |
| Q1 2025 | -1.2% | -1.6% | -0.6% | |
| Q4 2024 | -4.9% | -12.3% | -18.2% | |
| Q3 2024 | +8.1% | -4.4% | +0.8% | |
| Q2 2024 | +19.4% | +18.5% | +43.1% | |
| Q1 2024 | +0.8% | -1.1% | +8.1% | |
| Q4 2023 | -0.2% | +2.1% | -19.6% | |
| Q3 2023 | +6.8% | +13.4% | +7.1% | |
| Q2 2023 | +3.6% | -4.2% | +1.0% | |
| Q1 2023 | +0.2% | +0.9% | -0.4% | |
| Q4 2022 | -1.3% | -3.1% | +21.0% | |
| Q3 2022 | +5.3% | +4.7% | +15.1% | |
| Q2 2022 | -14.6% | -22.4% | -19.4% | |
| Q1 2022 | +2.0% | -15.7% | -21.1% | |
| Q4 2021 | -0.2% | +9.6% | -3.0% | |
| Q3 2021 | +2.5% | +9.3% | -9.9% | |
| Q1 2021 | +1.7% | +3.4% | +2.1% | |
| Q2 2021 | +1.7% | +3.4% | +2.1% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro